This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

The Interaction of Per-O-Acetylated Acyclic 1-(1-Butylindol-3-yl)-1-deoxy-ketoses with Silylated Uracil

S. N. Lavrenov^a; N. P. Solovyeva^b; M. I. Reznikova^a; O. S. Anisimova^b; M. N. Preobrazhenskaya^a Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia ^b Center for Drug Research, Russian Research Chimico-Pharmaceutical Institute, Moscow, Russia

Online publication date: 02 October 2004

To cite this Article Lavrenov, S. N. , Solovyeva, N. P. , Reznikova, M. I. , Anisimova, O. S. and Preobrazhenskaya, M. N.(2004) 'The Interaction of Per-O-Acetylated Acyclic 1-(1-Butylindol-3-yl)-1-deoxy-ketoses with Silylated Uracil ', Nucleosides, Nucleotides and Nucleic Acids, 23: 1, 281 - 289

To link to this Article: DOI: 10.1081/NCN-120027835 URL: http://dx.doi.org/10.1081/NCN-120027835

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS Vol. 23, Nos. 1 & 2, pp. 281–289, 2004

The Interaction of Per-O-Acetylated Acyclic 1-(1-Butylindol-3-yl)-1-deoxy-ketoses with Silylated Uracil[†]

S. N. Lavrenov, N. P. Solovyeva, M. I. Reznikova, O. S. Anisimova, and M. N. Preobrazhenskaya, **

 ¹Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
²Center for Drug Research, Russian Research Chimico-Pharmaceutical Institute, Moscow, Russia

ABSTRACT

The per-O-acetylated open chain derivatives of 1-(1-butylindol-3-yl)-1-deoxy-1-L-sorbose and 1-(1-butylindol-3-yl)-1-deoxy-L-tagatose, which are readily available by alkaline degradation of 1-butylascorbigen followed by acetylation, were used in a nucleoside-type synthesis. The interaction of these ketoses derivatives with bis-(trimethylsilyl)-uracil yielded in each case a mixture of (E)-2,4,5,6-tetra-O-acetyl-1-(1-butylindol-3-yl)-1,3-dideoxy-3-(uracil-1-yl)-L-*xylo*-hexa-1-enitol and (E)-2,4,5,6-tetra-O-acetyl-1-(1-butylindol-3-yl)-1,3-dideoxy-3-(uracil-1-yl)-L-*lyxo*-hexa-1-enitol, which were separated by preparative HPLC. The deacetylation of each of these compounds by MeONa in MeOH produced a mixture of 1-(1-butylindol-3-yl)-1,3-dideoxy-4-O-methyl-3-(uracil-1-yl)- α -L-sorbopyranose and 1-(1-butylindol-3-yl)-1,3-dideoxy-4-O-methyl-3-(uracil-1-yl)- β -D-fructopyranose, which were also separated by HPLC, the structures were confirmed by NMR.

Key Words: 1-Deoxy-1-(indol-3-yl)ketoses; Uracil; C-ketosides.

1525-7770 (Print); 1532-2335 (Online)

www.dekker.com

[†]In honor and celebration of the 70th birthday of Professor Leroy B. Townsend.

^{*}Correspondence: M. N. Preobrazhenskaya, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, B. Pirogovskaya str. 11, Moscow 119021, Russia; E-mail: mnp@space.ru.

282 Lavrenov et al.

INTRODUCTION

Whereas heteroaryl-containing aldoses and ketoses are rather rare compounds, a mixture of 1-deoxy-1-(indol-3-yl)-L-sorbose (**2a**) and 1-deoxy-1-(indol-3-yl)-L-tagatose (**3a**) can be readily obtained by the alkaline degradation of ascorbigen which is 2-C-[(indol-3-yl)methyl]- α -L-xylo-hex-3-ulofuranosono-4-lactone (**1a**). N-Substituted ascorbigens represent a good source of the corresponding N-substituted indolylketoses (Scheme 1). Recently we have shown that the mixture of diastereomeric ketoses underwent acetylation and pyranose ring opening under the action of acetic anhydride in pyridine in the presence of DMAP with the formation of a mixture of (*E*)-2,3,4,5,6-penta-O-acetyl-1-deoxy-1-(indol-3-yl)-L-xylo-hex-1-enitol (**4a**) and (*E*)-1-deoxy-1-(indol-3-yl)-L-xylo-hex-1-enitol (**5a**), which were separated chromatographycally. The goal of this work was to study a possibility of usage of these compounds in the synthesis of nucleoside analogs.

RESULTS AND DISCUSSION

The starting ketoses **2b** and **3b** were obtained by the alkaline degradation of N-butylascorbigen as previously described. The action of Ac_2O in pyridine in the presence of DMAP produced (*E*)-2,3,4,5,6-penta-O-acetyl-1-(1-butylindol-3-yl)-1-de-oxy-L-*xylo*-hex-1-enitol (**4b**) and (*E*)-2,3,4,5,6-penta-O-acetyl-1-(1-butylindol-3-yl)-1-deoxy-L-*lyxo*-hex-1-enitol (**5b**) as previously described for the ketoses obtained from

Scheme 1.



ascorbigen and 1-methylascorbigen. The interaction of the individual **4b** or **5b** with bis-(trimethylsilyl)-uracil (**8**) in the presence of $SnCl_4$ or $Me_3SiSO_3CF_3$ in acetonitrile gave a mixture of (E)-2,4,5,6-tetra-O-acetyl-1-(1-butylindol-3-yl)-1,3-dideoxy-3-(uracil-1-yl)-L-xylo-hexa-1-enitol (**6**) and (E)-2,4,5,6-tetra-O-acetyl-1-(1-butylindol-3-yl)-1,3-dideoxy-3-(uracil-1-yl)-L-lyxo-hexa-1-enitol (**7**) in \sim 80 % yield in both cases. The mixture of the acetylated ketoses **4b** and **5b** also gave a mixture of **6** and **7**. We failed to separate **6** and **7** by TLC or column chromatography methods. NMR spectra demonstrated two sets of signals typical for the two diastereomers. The compounds were separated by preparative HPLC. Mass-spectra of both compounds were similar and had the peaks of molecular ions (m/z 597), corresponding to the molecular weight of **4b** or **5b** and also the peaks corresponding to [N-Bu-indole-CH₂] fragment, uracil fragment and to the products of the consequent splitting of acetic acid or/and acetyl groups. As each of compounds **4b** and **5b** produced one and the same mixture of the two compounds **6** and **7**, it suggests that the attack of the silylated uracil is directed to the position 3 of the ketoses chains.

REPRINTS

The interaction of uracil with compounds **4b** or **5b** supposedly proceeds *via* intermediate acyloxonium ion **9** which is attacked by bis-(trimethylsilyl)-uracil **8** on the 3-C atom to give a mixture of diastereomers (Scheme 2).

Deacetylation of compounds 6 and 7 was performed by NaOMe in methanol. Mixtures of two compounds 10 and 11 were isolated in ~ 35 % yield from the

i) SnCl₄ or Me₃SiSO₃CF₃; MeCN ii) NaOMe/MeOH

Scheme 2.

284 Lavrenov et al.

d;**d**; $^3J_{5,6} = 8 \text{ N}H$: **s**, 8.19 5.76 **d**;**d**; $^3J_{5,6} = 8$ Table 1. ¹H NMR chemical shifts (δ) and coupling constants J (Hz) of carbohydrate moieties of compounds 4b; 5b; 6; 7; 10; 11 in CDCl₃. **d**; $^3J_{5,6} = 8$; NH: **s**, 8.40 $\mathbf{d};\mathbf{d};^3J_{5,6}=8$ 6-H; 5-H 7.61; NH: s, 8.40 6-H; 5-H 7.77; Uracil NH:s, 8.18 7.65; 5.68 7.82; 5.78 5.64 **d**; 6-H; 5-H 6-H; 5-H $\mathbf{d}_{\bullet}^{3}J_{\text{5-OH,5H}} = 3.9$ 2-OH: 2.71, Others 4-OCH₃:3.36,**s**; 5-OH: 2.57, **bs** 2.00 s;s;s;s;s **s;s;s**; (OAc) s;s;s;s (OAc) 2.04 s;s;s;s and OCH₃ OAc; OH 5-OH: 2.20; 2.23; 2.14; 2.06; 2.01; **d**, ⁴*J*_{2-OH}, 2.03; 2.02 2.11;2.05; $\mathbf{d,}^4 J_{2\text{-OH}},$ $_{3\text{H}} = 1.8;$ 2.03;2.02 2-OH: 2.75, 2.15; 2.10; 2.14; 2.05; 2.26; 2.12; $_{3H} = 1.8;$ 3.45, s; (OAc) (OAc) $4-0CH_3$: Ind N-CH, 4.09 **t** 4.08 **t** 4.07 t 4.07 t 4.05 m 4.06 m $(^{2}J_{6b,6a})[^{3}J_{6b,5}]$ (11,7) [6,5] (11,7) [7,6] J = 11.23.97 **dd** 4.05 **dd** 3.59 t 3.85 narrow **m** $H-6_a$ $(^2J_{6a,6b})$ $[^3J_{6a,5}]$ (11,7) [5,3] (11,7) [4,9] (11.2) [6.0] (12.1) [4.4] (11,6) [6,0] 5.45 m 4.31 dd 5.49 m 4.24 dd 5.35 m 4.29 dd 5.52 m 4.35 dd 3.95 m 3.72 dd 4.21 m H-5 Carbohydrate moiety $(^3J_{4,3})[^3J_{4,5}]$ (11.2) [3.4] (10.8) [8.5] (8,2) [3,2] (8,9) [2,9] (8.2) [4.4] 5.59 **dd** 5.78 **dd** 5.75 **dd** 3.68 **dd** 3.75 **dd** 5.58 s $^4J_{3H,2OH} = 1.8$ $^4J_{3H,2OH} = 1.8$ 4.84 **dd** (10.8) 5.22 **dd** (11.2) 5.69 d (8,2) 5.83 d (8,9) 5,58 d (8.2) H-3 (3J3,4) $\mathbf{d}; \mathbf{d}^2 J = 14.6$ $\mathbf{d}; \mathbf{d}^2 J = 14.4$ 2.80; 3.11 2.84; 3.23 6.85 s 8 09.9 89.9 6.58 s H-1 Compound/ solvent € Sp 2 Ξ 9 **_**

*: In all spectra there are also signals:

¹⁾ Of indole ring: 1 singlet, 2 doublets and 2 triplets in the area $\sim 7-8$ ppm.

²⁾ Of N-butyl group (except for triplet N-CH₂ given in the table): 3 multiplets in the area $\sim 0.8-1.8$ ppm.



individual 6 or 7 after NaOMe/MeOH treatment and consequent column chromatography as shown by NMR and HPLC. Compounds 10 and 11 were separated by preparative HPLC. A mixture of 6+7 similarly gave the same mixture of compounds 10 and 11. Unexpectedly to get totally deacetylated compounds it was necessary to use

about 10 equivalents of NaOMe. The analyses of mass-spectra of these compounds revealed that each of them contains a methyl group in the structure.

¹H NMR data for the compounds obtained are presented in Table 1. NMR methods assigned these compounds as epimeric at C-5 1-(1-butylindol-3-yl)-1,3-dideoxy-4-Omethyl-3-(uracil-1-yl)-\alpha-L-sorbopyranose (10) and 1-(1-butylindol-3-yl)-1,3-dideoxy-4-O-methyl-3-(uracil-1-yl)-β-D-fructopyranose (11). Structural assignments of 10 and 11 was based on the analysis of two-dimensional COSY spectra, spin decoupling and on deuterium exchange experiments. Spin-spin coupling constants in ¹H-NMR spectrum of compound 10 (${}^{3}J_{3,4} = 10.8$ Hz; ${}^{3}J_{4,5} = 8.5$ Hz) demonstrated that hydrogen atoms of carbohydrate skeleton at C-3 (d, 4.84 ppm), C-4 (q., 3.68 ppm.) and C-5 (m, 3,95 ppm) are axial atoms of a hexapyranose ring. A narrow doublet at 2.75 ppm in the ¹H NMR spectrum of 10, which disappeared after the addition of two drops of CD₃OD to CDCl₃ solution as a result of deuterium exchange was identified as 2-OH proton, which participated in long range spin-spin interaction with a hydrogen atom at 4.84 ppm (q, 3- H_{ax}) (through 4 bonds in W-type disposition, ${}^4J_{C2OH, C3Hax} = 1.8 \text{ Hz}$). A broad doublet at 2.20 ppm was attributed as the 5-OH hydrogen atom, which has vicinal spin-spin interaction with 5-H_{ax} (m, 3.95 ppm, ${}^{3}J_{C5OH, C5 Hax} = 3.9 Hz$). Signals in ${}^{1}H$ NMR spectrum of 11 were identified by similar way.

As it follows from the vicinal spin-spin constants values 3-H and 4-H in compound **11** are *axial* similarly to these atoms in compound **10**, but 5-H atom in compound 11 is *equatorial* and 5-OH atom is *axial*. It follows from the values of spin-spin coupling constants for 4-H (${}^{3}J_{3H, 4H} = 11.2$ Hz; ${}^{3}J_{4H, 5H} = 3.4$ Hz). In this compound 2-OH hydrogen atom also interacts through four bonds with 3-H_{ax} (${}^{4}J_{2-OH,3-Hax} = 1.8$ Hz). It assumes that 2-OH is *axial*.

NOEDIF experiments supported these structures. Figure 1 presents data of NOEDIF experiments showing the disposition of the substituents in compounds 10 and 11. These data support 2-OH *axial* configuration in 10 and 11, 5-H *axial* and 5-OH *equatorial* positions in 10 and 5-H *equatorial* and 5-OH *axial* positions in 11.




Figure 1. Data of NOEDIF experiments (in %) showing the positions of substituents in compounds 10 and 11.

286 Lavrenov et al.

Scheme 3.

It is important to emphasize that independently on configuration at 3-C in starting compounds **6** and **7** both deacetylated compounds **10** and **11** have similar (3*S*,4*S*) configurations. Compound **10** preserved 5*S* stereochemistry (as in starting **6** or **7**), whereas compound **11** isomerized into (5*R*) derivative, i.e. turned from L into D-compound. This result supports the hypothesis that the transformation of **6** and **7** under the action of MeONa in MeOH does not proceed as a Zemplen trans-esterefication reaction. In the reaction conditions compounds **6** and **7** split of acetic acid, which results in the formation of intermediates **12** and then **13** capable of epimerization at C-3. MeOH is added to the C4=C5 double bond followed by formation of a pyranose cycles with the conformationally preferable disposition of the substituents. Earlier we have demonstrated easy dehydration of compound **14** and formation of dienone **15** which underwent further transformations. [3,4]

Compounds 10 and 11 belong to a rare class of ketosides containing a nucleoside base moiety. The usage of ascorbigen degradation products in glycosylation reactions can provide a valuable analogs of nucleosides of new types. Biological properties of the compounds of these types remain to be investigated.

EXPERIMENTAL

NMR spectra were registered on a Varian Unity Plus instrument (400 MHz). Analytical TLC was performed on Kieselgel F_{254} plates (E.Merck), preparative TLC chromatography on plates (20 \times 20 cm, 0.5 mm) with Kieselgel 60 F_{254} (E.Merck), and column chromatography on Kieselgel 60 (E.Merck), using the following systems of





solvents: A (petroleum ether-EtOAc, 3:2), B (petroleum ether-EtOAc, 2:1), C (CHCl₃-

CH₃OH, 5:1). All solutions were dried over sodium sulfate and evaporated at reduced pressure on a Buchi rotary evaporator. Optical rotations were measured on a Perkin-Elmer 241 polarimeter.

High resolution mass spectra were registered on a MAT 8430 Finnigan instrument (USA) with data operating system SS-300 (EI, 70 eV, direct introduction, temperature of ion source 250°C). Electron impact (EI) mass-spectra were registered on a SSQ 710 Finnigan MAT instrument (USA), (EI: 70 eV, direct introduction). Analytical HPLC analyses were performed on a Millichrom 5 instrument (Russia), using a Diasorb C 16 column (2 × 120 mm and particle size 7 μ m), injection volume 5 μ l, detection at 280 nm, by isocratic elution, using systems of solvents: #1 (H₂O-CH₃CN, 45:55) and #2 (H₂O-CH₃CN, 60:40). Preparative HPLC were performed on a Shimadzu HPLC series LC 10 using a Diasorb C 16 column (15 × 250 mm and particle size 7 μ m), with injection volume 50 μ l, detection at 280 nm, using the same systems of solvents. Melting points were determined on a Buchi SMP-20 apparatus and are uncorrected.

(*E*)-1-Deoxy-1-(1-butylindol-3-yl)-2,3,4,5,6-penta-O-acetyl-L-*xylo*-hex-1-enitol (4b) and (*E*)-1-deoxy-1-(1-butylindol-3-yl)-2,3,4,5,6-penta-O-acetyl-L-*lyxo*-hex-1-enitol (5b). A solution of 2b and 3b mixture^[1] (1.3 g, 3.7 mmol) and DMAP (60 mg) in dry pyridine (20 mL) was cooled to -10° C, then Ac₂O (2.52 mL, 26.64 mmol) was added, and the mixture was left at room temperature for 12 h. It was then dissolved in 1N HCl (300 mL), and extracted with ether (3 × 50 mL). The extract was washed by brine, dried over Na₂SO₄ and evaporated *in vacuo* to give a mixture (1.8 g, 81%) of 4b and 5b as brown crystals. It was chromatographed on column with silica gel (system A), the fractions were evaporated, and after crystallizing from ether gave individual 4b (1 g, 40 %) and 5b (0.4 g, 20%).

4b: White crystals, mp 88–90°C (CHCl₃); $[\alpha]_D^{20} - 8.5^\circ$ (*C* 2.5, CHCl₃); R_f 0.46 (B); Anal. Calcd for $C_{28}H_{35}NO_{10}$: C, 61.63; H, 6.47; N, 2.57. Found: C, 61.56; H, 6.58; N. 2.44.

5b: White crystals, mp $104-106^{\circ}$ C (CHCl₃); $[\alpha]_{D}^{20} + 3^{\circ}$ (C 2.5, CHCl₃); R_{f} 0.54 (B); Anal. Calcd for $C_{28}H_{35}NO_{10}$: C, 61.63; H, 6.47; N, 2.57. Found: C, 61.79; H, 6.38; N, 2.40.

(*E*)-1,3-Dideoxy-1-(1-butylindol-3-yl)-3-(uracil-1-yl)-2,4,5,6-tetra-O-acetyl-L-xylo-hex-1-enitol (6) and (*E*)-1-dideoxy-1-(1-butylindol-3-yl)-3-(uracil-1-yl)-2,4,5,6-tetra-O-acetyl-L-lyxo-hex-1-enitol (7). To a solution of 4b (or 5b or a mixture 4b + 5b) in dry acetonitrile (10 mL) was added bis-(trimethylsilyl)-uracil 8 (775 mg, 3 mmol) and then $SnCl_4$ (0.24 mL, 2 mmol); after 30 min the reaction mixture was diluted with water (100 mL) and the products were extracted with ether (3 x 10 mL). The extract was dried with Na_2SO_4 and evaporated to give a mixture of 6 and 7(510 mg, 85 %) with R_f 0.65 (C) as yellow oil.

The individual $\bf 6$ and 7 were obtained with the use of preparative HPLC using 20 mg/mL solution in CH₃CN in system # 1, flow rate 3.0 mL/min, R_t 35.4 and 40.1 min respectively.

6: Yellow amorphous powder. Analytical HPLC: R_t 11.5 min (system # 1). EI-MS, *m/z* (%): 597 (M⁺, 30%); 555 (M-Ac, 100%); 495 (M-Ac-AcOH, 25%); 435 (M-Ac-2AcOH, 15%); 375 (M-Ac-3AcOH, 55%); 186 (N-BuInd-CH₂, 70%); 112 (uracil, 10%). HR-MS calc. for C₃₀H₃₅N₃O₁₀ 597.2323 found 597.2312.

288 Lavrenov et al.

7: Yellow amorphous powder. Analytical HPLC: R_t 13.0 min (system #1). EI-MS, m/z (%): 597 (M⁺, 20%); 555 (M-Ac, 100%); 495 (M-Ac-AcOH, 15%); 435 (M-Ac-2AcOH, 15%); 375 (M-Ac-3AcOH, 50%); 186 (N-BuInd-CH₂, 65%); 112 (uracil 15%). HR-MS calc. for $C_{30}H_{35}N_3O_{10}$ 597.2323 found 597.2310.

1,3-Dideoxy-1-(1-butylindol-3-yl)-3-(uracil-1-yl)-4-O-methyl-α-L-sorbopyranose (10) and 1,3-dideoxy-1-(1-butylindol-3-yl)-3-(uracil-1-yl)-4-O-methyl- β -D-fructopyranose (11). To a solution of a mixture of 6 and 7 (500 mg, 0.84 mmol) in methanol (10 mL) was added 2N solution of MeONa (~10 mmol) under argon. Then the reaction mixture was diluted with 5% NaHSO₄ solution and the products were extracted with ethyl acetate. The extract was dried over Na₂SO₄, evaporated and the products were purified by column chromatography (a system) to produce a mixture of 10 and 11 (130 mg, 35%) as amorphous yellowish powder, R_f 0.28 (C). The individual 10 and 11 were obtained by HPLC (sample concentration 15 mg/mL in CH₃CN, system #2, flow rate 3.0 mL/min, R_t 34.4 and 36.5 min respectively).

10: Colorless amorphous powder; $[\alpha]_D^{20} + 7.5^{\circ}$ (C 1.5, MeOH); analytical HPLC R_t 8.4 min (system # 2); EI-MS, m/z (%): 443 (M⁺, 50%); 425 (M-H₂O, 40%); 407 (M-2H₂O, 40%); 393 (M-H₂O-MeO, 100%); 295 (M-2H₂O-uracil, 65%); 186 (N-BuInd-CH₂, 80%).

HR-MS calc. for $C_{23}H_{29}N_3O_6$ 443.2056 found 443.2036.

11: Colorless amorphous powder; $[\alpha]_D^{20} - 4^{\circ}$ (C 2.2, MeOH); analytical. HPLC R_t 8.9 min (system # 2); EI-MS, m/z (%): 443 (M⁺, 40%); 425 (M-H₂O, 40%); 407 (M-2H₂O, 20%); 393 (M-H₂O-MeO, 100%); 295 (M-2H₂O-uracil, 60%); 186 (N-BuInd-CH₂, 90%).

HR-MS calc. for $C_{23}H_{29}N_3O_6$ 443.2056 found 443.2038.

ACKNOWLEDGMENTS

The work was supported by the Russian Foundation for Basic Research, project 03-03-32090. Authors thank Dr. Alexander M. Korolev for fruitful discussion.

REFERENCES

- Preobrazhenskaya, M.N.; Lazhko, E.I.; Korolev, A.M.; Reznikova, M.I.; Rozhkov, I.I. Transformation of ascorbigen into 1-deoxy-1-(indol-3-yl)-α-L-sorbopyranose and 1-deoxy-1-(indol-3-yl)-α-L-tagatopyranose. Tetrahedron: Asymmetry 1996, 7, 461–466.
- 2. Lavrenov, S.N.; Korolev, A.M.; Reznikova, M.I.; Sosnov, A.V.; Preobrazhenskaya, M.N. Study of 1-deoxy-1-(indol-1-yl)-L-sorbose, 1-deoxy-1-(indol-1-yl)-L-tagatose, and their analogs. Carbohydr. Res. **2003**, *338*, 143–152.
- 3. Korolev, A.M.; Yudina, L.N.; Rozhkov, I.I.; Lysenkova, L.N.; Lazhko, E.I.; Luzikov, Y.N.; Preobrazhenskaya, M.N. The formation of 2-hydroxy-4-hydroxymethyl-3-(indol-3-yl)cyclopent-2-enone derivatives from ascorbigens. Carbohydr. Res. **2001**, *330*, 469–477.



Acyclic 1-(1-Butylindol-3-yl)-1-deoxy-ketoses

4. Lysenkova, L.N.; Reznikova, M.I.; Korolev, A.M.; Preobrazhenskaya, M.N. Study of the transformation of 2-*C*-(indol-3-yl)methyl-α-L-*xylo*-hex-3-ulofuranosonic acid (the open form of ascorbigen) in an acidic medium. Russ. Chem. Bull. Int., Ed. **2001**, *50*, 1309–1313.

Received July 15, 2003 Accepted October 17, 2003 289

Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/ Order Reprints" link below and follow the instructions. Visit the U.S. Copyright Office for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on Fair Use in the Classroom.

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our Website User Agreement for more details.

Request Permission/Order Reprints

Reprints of this article can also be ordered at http://www.dekker.com/servlet/product/DOI/101081NCN120027835